INOVIQ’s Breakthrough Cancer Treatment Shows 88% Efficacy in Lab Tests

Inoviq Ltd ( (AU:IIQ) ) has provided an announcement.

INOVIQ Ltd has announced a significant breakthrough in its exosome therapeutic program, with lab tests showing that its new cancer treatment kills 88% of triple-negative breast cancer and lung cancer cells. This innovative treatment uses engineered immune cell particles, CAR-NK-EVs, which target and kill cancer cells more precisely. The treatment could potentially be faster, safer, and more effective than traditional therapies, offering an ‘off-the-shelf’ solution that could benefit many patients. The next step involves testing in animal models before progressing to human clinical trials, marking a promising advancement in cancer treatment options.

More about Inoviq Ltd

INOVIQ Ltd is a leader in exosome technology, focusing on next-generation diagnostics and therapeutics to transform cancer care and improve patient outcomes. The company’s product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical-stage CAR-exosome therapeutic program targeting solid tumors such as triple-negative breast cancer and lung cancer.

Average Trading Volume: 183,630

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$44.65M

Learn more about IIQ stock on TipRanks’ Stock Analysis page.